Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | USP9X | Q93008 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.31 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382273 | 1.00 | EPHX2 (0.38) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL574344 | 0.98 | EPHX2 (0.38) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL13890730 | 0.93 | — | — | |
| SCHEMBL57030 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL28314935 | 0.86 | — | — | |
| Ether SCHEMBL2398678 | 0.86 | ELOVL1 (0.33) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL14704914 | 0.81 | MEN1 (0.38) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL1455913 | 0.80 | EPHX2 (0.37) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL30206149 | 0.79 | EPHX2 (0.37) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL2731895 | 0.79 | HTR6 (0.38) | EPHX2ELOVL1HCAR2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150593-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2017-04-05 | — | — | EP | claimed |
| EP-0676429-B1 | Composition for urethane-based plastic lens | MITSUI CHEMICALS INC (JP) | 2000-12-27 | — | — | EP | claimed |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12303496-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| CN-113195053-B | Amino acid compounds and methods of use | 普利安特治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240100032-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-11696912-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230107360-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2023-04-06 | — | — | US | disclosed |
| CN-115650985-A | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2009073153-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INSTITUTE (US) | 2009-06-11 | — | — | WO | disclosed |
| CN-1520298-A | Pyrazolopyrimidines as therapeutic agents | �����ʩ���عɷݹ�˾ | 2004-08-11 | — | — | CN | disclosed |
| EP-0676429-B1 | Composition for urethane-based plastic lens | MITSUI CHEMICALS INC (JP) | 2000-12-27 | — | — | EP | disclosed |
| CN-1056858-C | Composition for urethane-base plastic lens, urethane-base plastic lens obtained from the composition and process for the production of the plastic lens | MITSUI TOATSU CHEMICALS (JP) | 2000-09-27 | — | — | CN | disclosed |
| US-6083969-A | 2,3-DIARYLPYRAZOLES FUSED WITH CYCLOALKANES AND CYCLOALKENES, USED AS CYCLOOXYGENASE-2 (COX-2) INHIBITOR | ORTHO-MCNEIL PHARACEUTICAL, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-5693738-A | REACTING AN ISOCYANATE AND/OR AN ISOTHIOCYANATE COMPOUND WITH A HYDROXYL AND/OR MERCAPTO-CONTAINING COMPOUND IN THE PRESENCE OF A COMPLEX OF A TERTIARY AMINE AND A LEWIS ACID | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-12-02 | — | — | US | disclosed |
| CN-1119195-A | Composition for urethane-base plastic lens, urethane-base plastic lens obtained from the composition and process for the production of the plastic lens | MITSUI TOATSU CHEMICALS (JP) | 1996-03-27 | — | — | CN | disclosed |
| EP-0676429-A2 | Composition for urethane-base plastic lens | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-10-11 | — | — | EP | disclosed |
| US-5246914-A | Fungicides and plant growth regulators | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12303496-B2 | Charged ion channel blockers and methods for use | TRPV1, ASIC1, TRPA1 | EPHX2 873/4885ELOVL1 1303/4885HCAR2 407/4885 |
| US-20240100032-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, ASIC1, TRPA1 | EPHX2 873/4885ELOVL1 1303/4885HCAR2 407/4885 |
| US-11696912-B2 | Charged ion channel blockers and methods for use | TRPV1, ASIC1, TRPA1 | EPHX2 873/4885ELOVL1 1303/4885HCAR2 407/4885 |
| US-20230107360-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | EPHX2 855/4885ELOVL1 1371/4885HCAR2 432/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | EPHX2 4541/4885ELOVL1 622/4885HCAR2 2933/4885 |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | OPRL1, TRPV1, SCN2B | EPHX2 870/4885ELOVL1 3038/4885HCAR2 203/4885 |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | ITGB6, ITGA1, ITGB1 | EPHX2 4541/4885ELOVL1 622/4885HCAR2 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.